Evidence map›Paper›PMID 35740650›Full record

ArticleCancers2022

Low-Dose Metronomic Topotecan and Pazopanib (TOPAZ) in Children with Relapsed or Refractory Solid Tumors: A C17 Canadian Phase I Clinical Trial.

Arif Manji, Yvan Samson, Rebecca J Deyell, Donna L Johnston, Victor A Lewis, Alexandra P Zorzi, Jason N Berman, Kathy Brodeur-Robb, Ellen Morrison, Lynn Kee and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Arif ManjiThe Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada.
Yvan SamsonCHU Sainte-Justine, Montréal, QC H3T 1C5, Canada.
Rebecca J DeyellBC Children's Hospital, Vancouver, BC V6H 3N1, Canada.
Donna L JohnstonChildren's Hospital of Eastern Ontario, Ottawa, ON K1H 8L1, Canada.
Victor A LewisAlberta Children's Hospital, Calgary, AB T3B 6A8, Canada.
Alexandra P ZorziChildren's Hospital, London Health Sciences Centre, London, ON N6A 5W9, Canada.
Jason N BermanChildren's Hospital of Eastern Ontario, Ottawa, ON K1H 8L1, Canada.
Kathy Brodeur-RobbC17 Council for Children's Cancer and Blood Disorders, Edmonton, AB T6G 2E1, Canada.
Ellen MorrisonC17 Council for Children's Cancer and Blood Disorders, Edmonton, AB T6G 2E1, Canada.
Lynn KeeThe Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada.
Sushil KumarDrug Metabolism & Pharmacokinetics, QPS Holdings LLC, Newark, DE 19711, USA.
Sylvain BaruchelThe Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada.
James A WhitlockThe Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada.
Daniel A MorgensternThe Hospital for Sick Children, University of Toronto, Toronto, ON M5G 1X8, Canada.ORCID 0000-0002-4859-1108
University of Toronto · CAC17 Council · CAChildren's Hospital of Eastern Ontario · CAAlberta Children's Hospital · CABC Children's Hospital · CACentre Hospitalier Universitaire Sainte-Justine · CALondon Health Sciences Centre · CA

Funding

Curtis Chow Memorial Fund n/aGarron Family Cancer Centre n/aJames Fund for Neuroblastoma n/a
6 · The paper itself

Abstract

Oral metronomic topotecan represents a novel approach to chemotherapy delivery which, in preclinical models, may work synergistically with pazopanib in targeting angiogenesis. A phase I and pharmacokinetic (PK) study of this combination was performed in children with relapsed/refractory solid tumors. Oral topotecan and pazopanib were each administered daily without interruption in 28-day cycles at five dose levels (0.12 to 0.3 mg/m

Indexed as

angiogenesischildrenmetronomicpazopanibpediatricphase I trialtopotecan

Identifiers

PMID35740650
PMCPMC9221162
OpenAlexW4283070056

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.